Thomas Strüngmann

Overview
Thomas Strüngmann is a German business-trained entrepreneur, the commercial co-founder of the generic-pharmaceuticals company Hexal AG, and — with his identical twin brother Andreas Strüngmann — the anchor investor behind the 2008 founding of BioNTech SE. The brothers operate a Munich- and Zug-based family-office platform (Athos KG and Santo Holding GmbH) that has become one of Europe's most consequential dedicated life-sciences investment vehicles.
Why this entity matters
Thomas Strüngmann and his twin brother Andreas Strüngmann co-founded Hexal AG in Holzkirchen, Bavaria, in 1986 and sold it to Novartis on 21 February 2005 for approximately 5.65 billion euros — the largest private company sale in German history at the time. Three years later, in 2008, the brothers provided the foundational seed capital of approximately 150 million euros for BioNTech SE through the AT Impf 100 Beteiligungs GmbH holding vehicle. Held through eleven pre-IPO years, that position became a jointly controlled stake worth more than 50 billion US dollars at BioNTech's August 2021 market-capitalisation peak — one of the largest venture-capital returns on record and the direct enabling condition for Comirnaty (BNT162b2).
Career, company, or institutional background
Thomas Strüngmann was born in Germany in 1950 and grew up in Bavaria. He earned a degree in business administration at the University of Augsburg, complementing his twin brother Andreas Strüngmann's medical training at Freiburg and Buffalo. From 1986 through the 2005 Novartis transaction he served as the commercial-strategy co-lead of Hexal AG — driving pricing, penetration in the German generics segment, the acquisition of a 67.7 percent controlling interest in US generics company Eon Labs, and expansion into Asia and South Africa. By early 2005 Hexal was Germany's second-largest generics firm with approximately seven thousand employees and 2004 revenue of about 1.65 billion US dollars. Thomas Strüngmann briefly served on the Sandoz Executive Committee during the post-transaction integration. He then formalised, with Andreas Strüngmann, a family-office structure comprising Santo Holding GmbH (Zug), Athos Service GmbH and Athos KG (Munich), and special-purpose vehicles including AT Impf 100 Beteiligungs GmbH and ATS Beteiligungsverwaltung GmbH.
Role in the startup, technology, investment, or innovation ecosystem
The Strüngmann family office is a canonical DACH dynastic patient-capital anchor — long horizons, concentrated bets, and sustained backing of scientific founding teams across multiple companies. Beyond the BioNTech position, headline holdings include Ganymed Pharmaceuticals (Astellas exit 2016 for up to approximately 1.28 billion euros; lead asset later approved as VYLOY / zolbetuximab in 2024), WS Audiology (via the November 2014 joint acquisition of Siemens Audiology Solutions with EQT Private Equity for 2.15 billion euros), and Formycon AG (26.6 percent stake following a 2022 strategic asset merger of approximately 650 million euros); further biotechnology positions include AiCuris, Immatics, iOmx Therapeutics, Glycotope, AAVantgarde Bio, AMSilk, Antheia, Bambusa Therapeutics, NexWafe and SuppreMol.
Selected relationships and affiliations
Thomas Strüngmann co-founded Hexal AG with his twin brother Andreas Strüngmann, with whom he continues to invest jointly across the Athos portfolio — the family-ownership structure retains Hexal proceeds and subsequent portfolio positions as a single pool. The brothers together anchor Santo Holding GmbH, Athos KG, AT Impf 100 Beteiligungs GmbH and ATS Beteiligungsverwaltung GmbH. Their partnership with the scientific founding team of Uğur Şahin, Özlem Türeci and Christoph Huber began with the founding investment in Ganymed Pharmaceuticals in 2001 and continued through the 2008 BioNTech seed round and subsequent BioNTech financing rounds. The brothers co-founded, and named for their father Ernst Strüngmann, the Ernst Strüngmann Institute for Neuroscience in Frankfurt in partnership with the Max Planck Society; Ernst Strüngmann founded the small pharmaceutical company Durachemie. Thomas Strüngmann is additionally associated with philanthropic activity in Bavaria.
Startuprad.io relevance
Thomas Strüngmann, the 2005 Hexal-Novartis transaction, the BioNTech founding capital stack and the Athos portfolio appear across Startuprad.io editorial coverage — including the Medium companion analysis "Meet the Twin Billionaires Behind BioNTech's Success" and recurring DACH-ecosystem monthly news episodes covering the pandemic-era mRNA response. Thomas Strüngmann is a pillar entity in Startuprad.io's DACH dynastic patient-capital cluster alongside Susanne Klatten, Dietmar Hopp and Uğur Şahin.
Public source context
Public references include the https://en.wikipedia.org/wiki/Andreas_and_Thomas_Str%C3%BCngmann , https://www.wikidata.org/wiki/Q23773023 , the https://www.forbes.com/profile/thomas-struengmann/ and the https://en.wikipedia.org/wiki/Ernst_Str%C3%BCngmann_Institute .

About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.

Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/thomas-struengmann